Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0027819 (
neuroblastoma
)
27,800
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
DR-nm23
belongs to a gene family which includes nm23-H1, originally identified as a candidate metastasis suppressor gene. Nm23 genes are expressed in different tumor types where their levels have been alternatively associated with reduced or increased metastatic potential. Nm23-H1, -H2,
DR-nm23
and nm23-H4 all possess NDP kinase activity. Overexpression of
DR-nm23
inhibits differentiation and promotes apoptosis in hematopoietic cells. By contrast, it induces morphological and biochemical changes associated with neural differentiation in
neuroblastoma
cells. In this study, we show that mutations in the catalytic domain and in the serine 61 phosphorylation site, possibly required for protein-protein interactions, impair the ability of
DR-nm23
to induce neural differentiation. Moreover,
neuroblastoma
cells overexpressing wild-type or mutant
DR-nm23
are less sensitive to apoptosis triggered by serum withdrawal. By subcellular fractionation, wild-type and mutant
DR-nm23
localize in the cytoplasm and prevalently in the mitochondrial fraction. In co-immunoprecipitation experiments, wild-type
DR-nm23
binds other members of nm23 family, but mutations in the catalytic and in the RGD domains and in serine 61 inhibit the formation of hetero-multimers. Thus, the integrity of the NDP kinase activity and the presence of a serine residue in position 61 seem essential for the ability of
DR-nm23
to trigger differentiation and to bind other Nm23 proteins, but not for the anti-apoptotic effect in
neuroblastoma
cells. These studies underline the tissue specificity of the biological effects induced by
DR-nm23
expression.
...
PMID:Neuroblastoma specific effects of DR-nm23 and its mutant forms on differentiation and apoptosis. 1104 79